Hence, the optimal choice between conventional chemotherapy and immunotherapy for first-line therapy remains uncertain in patients with obesity who potentially have an inadequate therapeutic response to anti-PD–1 therapy. This evidence concerns the gene PDCD1 and obesity due to melanocortin 4 receptor deficiency.